MedTrace Logo

Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder

NCT01658150 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2018-12-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the use of the drug isradipine for cognitive enhancement in patients diagnosed with schizophrenia and schizoaffective disorder.

Conditions

Interventions

DRUG

isradipine

Isradipine is a medication that acts by blocking a specific type of receptor in the brain called a calcium channel

Sponsors & Collaborators

Principal Investigators

  • Katherine Burdick, PhD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2018-01-02
Completion
2018-01-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01658150 on ClinicalTrials.gov